Close

After-Hours Stock Movers 08/09: (CLNE) (OCN) (YELP) Higher; (GEVO) (SPWR) (MYGN) Lower (more...)

Go back to After-Hours Stock Movers 08/09: (CLNE) (OCN) (YELP) Higher; (GEVO) (SPWR) (MYGN) Lower (more...)

Jefferies Remains Sidelined on Myriad Genetics (MYGN) Following 4Q

August 11, 2016 8:37 AM EDT

Jefferies maintained a Hold rating on Myriad Genetics (NASDAQ: MYGN), and cut the price target to $20.00 (from $34.00), following the company's 4Q earnings report. The company's weaker 4Q16 experience (-7%) and initial FY17 outlook for the HC segment (-7%) suggest pricing and... More

Imperial Capital Raises Price Target on CyberArk Software (CYBR) to $55 Following 2Q

August 11, 2016 7:21 AM EDT

Imperial Capital reiterated an In-Line rating on CyberArk Software (NASDAQ: CYBR), and raised the price target to $55.00 (from $45.00), following the company's 2Q earnings report. CYBR reported revenue of $50.4mn and adjusted EPS of $0.29, compared with the Street revenue estimates of 48.3mn and adjusted EPS estimates... More

Piper Jaffray Remains Bearish on Fossil Group (FOSL) Following 2Q Results and Guidance

August 10, 2016 8:37 AM EDT

Piper Jaffray reiterated an Underweight rating and $25.00 Price Target on Fossil Group (NASDAQ: FOSL) following the company's 2Q earnings report and conference call. Sales were reported at $685M vs. $673M estimates. EPS was at $0.12 vs. the Street's $0.09. Q3 was issued well-below expectations. Sales are forecasted to be down 6%-2% vs. former -0.7%... More

Baird Remains Sidelined on Yelp (YELP) as Local Ad Strength Fuels 2Q Beat

August 10, 2016 7:48 AM EDT

Baird reiterated a Neutral rating on Yelp (NYSE: YELP), and raised the price target to $35.00 (from $25.00), following the company's 2Q earnings report. Revenue of $173.4M exceeded $169.1M estimates, while Local advertising revenue of $151.9M was also above consensus expectations of $147.8M. FY16... More

Mizuho Securities Cuts Price Target on Myriad Genetics (MYGN) to $22 Following 4Q and Guidance

August 10, 2016 7:19 AM EDT

Mizuho Securities maintained a Neutral rating on Myriad Genetics (NASDAQ: MYGN), and cut the price target to $22.00 (from $34.00), following the company's 4Q results and guidance. MYGN guided to 2017 revenues of $740mm-$760mm, versus consensus of $790mm, and EPS of $1.00-$1.10, versus consensus of $1.77.... More

Leerink Partners Raises price Target on Diplomat Pharmacy (DPLO) to $38 Following Mixed 2Q

August 10, 2016 7:07 AM EDT

Leerink Partners reiterated an Outperform rating on Diplomat Pharmacy (NYSE: DPLO), and raised the price target to $38.00 (from $36.00), following the company's 2Q earnings report. DPLO reported total revenue of $1,089M, 3% below consensus of $1,118M. Adjusted EPS $0.23 was above the consensus estimates of $0.21.

Analyst... More

Susquehanna Remains Sidelined on Yelp (YELP) Following Solid 4Q Results

August 10, 2016 6:59 AM EDT

Susquehanna reiterated a Neutral rating on Yelp (NYSE: YELP), and raised the price target to $35.00 (from $22.00), following the company's 2Q earnings report. Revenue was 2% above consensus, driven by higher local advertising, while transaction revenue came in slightly lower than consensus expectations. EPS of $0.16 was $0.01... More

FBR Capital Cuts Price Target on SolarEdge Technologies (SEDG) Following 4Q Report

August 10, 2016 6:53 AM EDT

FBR Capital maintained an Outperform rating on SolarEdge Technologies (NASDAQ: SEDG), and cut the price target to $32.00 (from $38.00), following the company's 4Q earnings report. SEDG delivered revenues of $124.8M and non-GAAP EPS of $0.44. The company also grew operating cash by $17.3M and now has $4.08/share in net cash.

Analyst Carter Driscoll commented, "Yesterday, August 9, SEDG delivered F4Q16... More